DRKS00006219CompletedNot Applicable
Extension of the EUROBservational Research Programme Atrial Fibrillation General Registry (EORP AFIB registry) for Germany - AFNET-EORP registry Atrial Fibrillation Germany
Die Register-Studie wird durchgeführt vom: Kompetenznetz Vorhofflimmern AFNET e.V.0 sites3,528 target enrollmentStarted: July 23, 2014Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 3,528
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 Years to one (—)
- Sex
- All
Inclusion Criteria
- •Patients will be officially enrolled in the study only if ECG diagnosis of AF has been made.
- •- The qualifying episode of AF should have occurred within one year before the date of baseline.
- •- AF is the primary or secondary diagnosis, i.e. the current admission / visit may be due to other reasons.
- •- Patients need not be in AF at the time of enrolment.
- •- Signed Patient Inform Consent
- •- Age <= 18 years
Exclusion Criteria
- •Patients who are currently or are planned to be taking part in a cardiac clinical trial.
- •Please note that patients can participate concomitantly in other registries.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Study to evaluate immunogenicity and safety of GSK Biologicals’ Herpes Zoster subunit (HZ/su) vaccine at 9 and 10 years after vaccine administration and assessment of re-vaccination with 2 additional doses at 10 years after initial vaccination, in healthy subjects aged 60 years of age and older.Herpes Zoster (HZ)MedDRA version: 18.1Level: PTClassification code 10019974Term: Herpes zosterSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.1Level: HLTClassification code 10019972Term: Herpes viral infectionsSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.1Level: HLGTClassification code 10047438Term: Viral infectious disordersSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.1Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-004400-30-CZGlaxoSmithKline Biologicals SA100
Active, not recruiting
Phase 1
Study to evaluate immunogenicity and safety of GSK Biologicals’ Herpes Zoster subunit (HZ/su) vaccine at 9 and 10 years after vaccine administration and assessment of re-vaccination with 2 additional doses at 10 years after initial vaccination, in healthy subjects aged 60 years of age and older.EUCTR2015-004400-30-DEGlaxoSmithKline Biologicals100
Active, not recruiting
Phase 1
ong-Term Safety and Efficacy of Asfotase Alfa in Children with Hypophosphatasia (HPP)MedDRA version: 20.0Level: PTClassification code 10049933Term: HypophosphatasiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersHypophosphatasiaEUCTR2017-003153-42-Outside-EU/EEAAlexion Pharma GmbH12
Not yet recruiting
Not Applicable
GO OBSERVE: A European observational study in adults with moderate to severe ulcerative colitis in which the patient reports his or her response to SIMPONI at home through a website.C, ulcerative colitis, IBD, golimumab, SIMPONINL-OMON22604MSD B.V.33
Completed
Not Applicable
An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients-G20 Parkinson´s diseaseParkinson´s diseaseG20PER-031-07SOLVAY PHARMACEUTICALS,